Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Open-Label, Phase 2 Safety Extension Study to Evaluate the Safety and Tolerability of R-107 in subjects with Refractory Major Depressive Disorder.

Trial Profile

A Multicentre, Open-Label, Phase 2 Safety Extension Study to Evaluate the Safety and Tolerability of R-107 in subjects with Refractory Major Depressive Disorder.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2018

At a glance

  • Drugs R 107 Radikal Therapeutics (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Acronyms BEDROC-1
  • Sponsors Douglas Pharmaceuticals
  • Most Recent Events

    • 12 Nov 2018 Planned End Date changed from 10 Apr 2020 to 2 Oct 2020.
    • 12 Nov 2018 Planned initiation date changed from 17 Sep 2018 to 19 Feb 2019.
    • 28 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top